Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 7/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174223 | 0.88 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL18174256 | 0.88 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL20132809 | 0.88 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL18174279 | 0.88 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL20132776 | 0.88 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL20132818 | 0.86 | IL6ST (0.45) | IL6STSTAT3AKT1IDH1 | |
| SCHEMBL4767695 | 0.81 | IL6ST (0.52) | IL6STSTAT3IDH1 | |
| SCHEMBL4770816 | 0.81 | IL6ST (0.52) | IL6STSTAT3IDH1 | |
| SCHEMBL4768353 | 0.79 | IL6ST (0.50) | IL6STSTAT3IDH1 | |
| SCHEMBL18174212 | 0.79 | IL6ST (0.45) | IL6STSTAT3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | IL6ST 374/4885DPP4 2969/4885FAP 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.